{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:18Z","timestamp":1790375358244,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation, Taiwan","doi-asserted-by":"crossref","award":["CMRPD1J0101-0102"],"award-info":[{"award-number":["CMRPD1J0101-0102"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation, Taiwan","doi-asserted-by":"crossref","award":["CMRPD1L0371"],"award-info":[{"award-number":["CMRPD1L0371"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitor (TKI) treatment has been identified to be a risk factor for metabolic syndrome and cardiovascular diseases (CVDs) in patients diagnosed with chronic myeloid leukemia (CML). However, the specific contribution of post-TKI metabolic syndrome and the individual TKIs, including imatinib, nilotinib, and dasatinib, contribute to the development of CVDs remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a nationwide database to investigate the incidence of post-TKI metabolic syndrome, including diabetes, hyperlipidemia, and hypertension, as well as their association with CVDs. To compare the risk of post-TKI comorbidities and CVDs among TKIs, we utilized the incidence rate ratio (IRR), and subdistribution hazard ratio (SHR) calculated from multiple Fine-Gray models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1211 patients without diabetes, 1235 patients without hyperlipidemia, and 1074 patients without hypertension were enrolled in the study. The incidence rate of post-TKI diabetes and hyperlipidemia was the highest in patients treated with nilotinib compared to imatinib and dasatinib (IRRs\u2005\u2265\u20053.15, Ps\u2005\u2264\u2005.047). After adjusting for confounders, nilotinib remained a significant risk factor for post-TKI diabetes and hyperlipidemia at an SHR of 3.83 (P\u2005&amp;lt;\u2005.001) and 5.15 (P\u2005&amp;lt;\u2005.001), respectively. Regarding the occurrence of CVDs, patients treated with nilotinib were more likely to develop CVDs than those treated with imatinib in non-hyperlipidemic group (IRR\u2005=\u20053.21, P\u2005=\u2005.020). Pre-existing and post-TKI hyperlipidemia were found to have a stronger association with CVDs, with SHR values of 5.81 (P\u2005=\u2005.034) and 13.21 (P\u2005=\u2005.001), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The findings of this study indicate that nilotinib treatment is associated with increased risks of diabetes and hyperlipidemia, with hyperlipidemia being the most significant risk for CVDs. Therefore, we recommend that CML patients receiving nilotinib should undergo screening for diabetes and hyperlipidemia prior to initiating TKI treatment. Additionally, regular monitoring of lipid profiles during TKI therapy and implementing effective management strategies to control hyperlipidemia are crucial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad225","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T19:51:50Z","timestamp":1691697110000},"page":"e81-e89","source":"Crossref","is-referenced-by-count":11,"title":["Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study"],"prefix":"10.1093","volume":"29","author":[{"given":"Cih-En","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital , Chiayi , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-1674","authenticated-orcid":false,"given":"Kuan-Der","family":"Lee","sequence":"additional","affiliation":[{"name":"Cell Therapy and Regenerative Medicine Center, Comprehensive Cancer Center, Taichung Veterans General Hospital , Taichung , Taiwan"},{"name":"International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of Medicine, School of Medicine, Taipei Medical University , Taipei , Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-0290","authenticated-orcid":false,"given":"Jung-Jung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Chang Gung Memorial Hospital , Chiayi , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-4361","authenticated-orcid":false,"given":"Huey-En","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Taichung Veterans General Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Public Health and Biostatistics Consulting Center, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-5570","authenticated-orcid":false,"given":"Lennex Hsueh-Lin","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Panco Healthcare Co., Ltd. , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-252X","authenticated-orcid":false,"given":"Min-Chi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Public Health and Biostatistics Consulting Center, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital , Chiayi , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"2024010523405200300_CIT0001","first-page":"2391","article-title":"2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume-title":"Blood","author":"Arber","year":"2016"},{"key":"2024010523405200300_CIT0002","first-page":"994","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume-title":"N Engl J Med","author":"O\u2019Brien","year":"2003"},{"key":"2024010523405200300_CIT0003","first-page":"917","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume-title":"N Engl J Med","author":"Hochhaus","year":"2017"},{"key":"2024010523405200300_CIT0004","first-page":"440","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume-title":"Leukemia","author":"Kantarjian","year":"2021"},{"key":"2024010523405200300_CIT0005","first-page":"2333","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume-title":"J Clin Oncol","author":"Cortes","year":"2016"},{"key":"2024010523405200300_CIT0006","first-page":"717","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume-title":"Haematologica","author":"Lee","year":"2016"},{"key":"2024010523405200300_CIT0007","first-page":"1344","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume-title":"Leukemia","author":"Radich","year":"2021"},{"key":"2024010523405200300_CIT0008","first-page":"650","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume-title":"Leuk Lymphoma","author":"Shah","year":"2020"},{"key":"2024010523405200300_CIT0009","first-page":"3671","article-title":"The new ELN recommendations for treating CML","volume-title":"J Clin Med","author":"Hehlmann","year":"2020"},{"key":"2024010523405200300_CIT0010","first-page":"901","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume-title":"Blood","author":"Valent","year":"2015"},{"key":"2024010523405200300_CIT0011","first-page":"4210","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume-title":"J Clin Oncol","author":"Moslehi","year":"2015"},{"key":"2024010523405200300_CIT0012","first-page":"1312","article-title":"Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study","volume-title":"Eur J Prev Cardiol","author":"Yang","year":"2022"},{"key":"2024010523405200300_CIT0013","first-page":"974","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study","volume-title":"Oncologist","author":"Chen","year":"2021"},{"key":"2024010523405200300_CIT0014","first-page":"1336","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume-title":"Leukemia","author":"Hoffmann","year":"2015"},{"key":"2024010523405200300_CIT0015","first-page":"15245","article-title":"Cardiovascular risk factors associated with acute myocardial infarction and stroke in the MADIABETES cohort","volume-title":"Sci Rep","author":"Salinero-Fort","year":"2021"},{"key":"2024010523405200300_CIT0016","first-page":"496","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume-title":"J Am Stat Assoc","author":"Fine","year":"1999"},{"key":"2024010523405200300_CIT0017","first-page":"1084","article-title":"The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia","volume-title":"Blood Adv","author":"Minson","year":"2019"},{"key":"2024010523405200300_CIT0018","first-page":"1044","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume-title":"Leukemia","author":"Hochhaus","year":"2016"},{"key":"2024010523405200300_CIT0019","first-page":"353","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US","volume-title":"Curr Med Res Opin","author":"Franklin","year":"2018"},{"key":"2024010523405200300_CIT0020","first-page":"2239","article-title":"Type 2 diabetes","volume-title":"Lancet","author":"Chatterjee","year":"2017"},{"key":"2024010523405200300_CIT0021","first-page":"1493","article-title":"The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008","volume-title":"Circulation","author":"Danaei","year":"2013"},{"key":"2024010523405200300_CIT0022","first-page":"1563","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume-title":"N Engl J Med","author":"Ginsberg","year":"2010"},{"key":"2024010523405200300_CIT0023","first-page":"e124","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume-title":"Haematologica","author":"Racil","year":"2013"},{"key":"2024010523405200300_CIT0024","first-page":"135","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume-title":"Int J Hematol","author":"Ito","year":"2013"},{"key":"2024010523405200300_CIT0025","first-page":"382","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia","volume-title":"J Clin Pharm Ther","author":"Abumiya","year":"2021"},{"key":"2024010523405200300_CIT0026","first-page":"71","article-title":"Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib","volume-title":"Exp Hematol","author":"Martino","year":"2017"},{"key":"2024010523405200300_CIT0027","first-page":"2295","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume-title":"N Engl J Med","author":"Rodgers","year":"2016"},{"key":"2024010523405200300_CIT0028","first-page":"2388","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume-title":"Leukemia","author":"Hadzijusufovic","year":"2017"},{"key":"2024010523405200300_CIT0029","first-page":"966","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume-title":"Leukemia","author":"Hochhaus","year":"2020"},{"key":"2024010523405200300_CIT0030","first-page":"191","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment, and monitoring","volume-title":"Hematol Transfus Cell Ther","author":"Seguro","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e81\/55119306\/oyad225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e81\/55119306\/oyad225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T23:44:02Z","timestamp":1704498242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/1\/e81\/7240615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,8,10]]}}}